Table 1.
Clinical Characteristics of 32 participants to whom three doses of CoronaVac Vaccine were administered.
| Characteristics | Value |
|---|---|
| Gender | |
| Female, N, (%) | 24 (75%) |
| Male, N, (%) | 8 (25%) |
| Age | |
| Female age (IQR), years | 34 (31–40) |
| Male age (IQR), years | 36 (31–42) a |
| Race | |
| Han, N, (%) | 32 (100%) |
| Vaccination schedule | |
| Days between the first dose and second dose (days) | 28 |
| Days between the second dose and third dose (days) | 248 |
| SARS-CoV-2 infection | |
| Before vaccination, N, (%) | 0 (0%) |
| After vaccination, N, (%) | 0 (0%) |
| Presenting COVID-19 symptoms: | |
| Cough, N, (%) | 0 (0%) |
| Fever, N, (%) | 0 (0%) |
| Sore throat, N, (%) | 0 (0%) |
| Fatigue, N, (%) | 0 (0%) |
| Diarrhea, N, (%) | 0 (0%) |
| Runny nose, N, (%) | 0 (0%) |
| Shortness of breath, N, (%) | 0 (0%) |
| Muscle aches, N, (%) | 0 (0%) |
| Loss of or change to a sense of smell and taste, N, (%) | 0 (0%) |
ap = 0.287, compared with female age; N, number; IQR, interquartile range.